Avastin adds non-small cell lung cancer to list of FDA approvals (Cancerfacts.com)
SAN FRANCISCO Oct. 11, 2006 Genentech, Inc. (NYSE: DNA) announced today that the FDA has approved Avastin (bevacizumab) to be used in combination with chemotherapy for treatment of certain types of non-small cell lung cancer.

Aspreva Announces Preliminary Revenues for Third Quarter 2006 and Reaffirms Guidance for the Year (PR Newswire via Yahoo! Finance)
Aspreva Pharmaceuticals Corporation , an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines for patients with less common diseases, today announced preliminary revenue of approximately US$48 million for the third quarter of 2006.